Trials of AccuSite Injectable Gel From Matrix Begin in Basal Cell Ca
MENLO PARK, Calif--Matrix Pharmaceutical, Inc. has initiated two phase III trials of its AccuSite injectable gel for patients with basal cell cancer. The company has completed phase III testing of the gel for the treatment of genital warts and expects to submit a new drug application to the FDA for that indication later this year.
MENLO PARK, Calif--Matrix Pharmaceutical, Inc. has initiated twophase III trials of its AccuSite injectable gel for patients withbasal cell cancer. The company has completed phase III testingof the gel for the treatment of genital warts and expects to submita new drug application to the FDA for that indication later thisyear.
One of the basal cell cancer trials is an open-label long-termsafety and efficacy study expected to enroll approximately 400patients from 20 to 25 sites in Europe, Australia, New Zealand,and the United States. The second trial is a placebo-controlledstudy involving 225 patients, designed to provide histologic confirmationof clinical response.
Targeted Therapy First Strategy Reduces Need for Chemotherapy in Newly Diagnosed LBCL
December 7th 2025Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone may allow 57% of patients with newly diagnosed LBCL to receive less than the standard number of chemotherapy cycles without compromising curative potential.
